Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder, and yet with no pharmacological treatment approved worldwide. The repositioning of old drugs provides a safe approach for drug development. Vidofludimus, an inhibitor for dihydroorotate dehydrogenase (DHODH)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yanlin, Xu, Shuangshuang, Lu, Yi, Wei, Yijuan, Yao, Benqiang, Guo, Fusheng, Zheng, Xing, Wang, Yumeng, He, Ying, Jin, Lihua, Li, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240069/
https://www.ncbi.nlm.nih.gov/pubmed/32477115
http://dx.doi.org/10.3389/fphar.2020.00590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240069/
https://www.ncbi.nlm.nih.gov/pubmed/32477115
http://dx.doi.org/10.3389/fphar.2020.00590

Ejemplares similares